MBX BIOSCIENCES INC.

19.83

26-November-24 16:45:00

15 minutes delayed

Stocks

+0.44

+2.27%

Today's range

19.67 - 20.78

ISIN

N/A

Source

NASDAQ

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

18 Nov 2024 08:00:00 By Nasdaq GlobeNewswire
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire
MBX Biosciences to Participate in Upcoming November Investor Conferences

28 Oct 2024 08:00:00 By Nasdaq GlobeNewswire
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.